Opinion|Videos|December 16, 2024
New Systemic Treatments for Prurigo Nodularis
Author(s)Melodie Young, MSN, ANP-C
Key Takeaways
- Prurigo nodularis diagnosis is challenging due to symptom overlap with other pruritic conditions and absence of specific tests.
- Increased prevalence is noted in patients with atopic dermatitis and other specific subtypes.
Melodie Young, MSN, A/GNP-C, discusses how the FDA-approved systemic treatments for prurigo nodularis, dupilumab and nevolizumabnemolizumab, differ in their mechanisms of action—dupilumab targeting IL-4 and IL-13, and nevolizumabnemolizumab targeting IL-31—and highlights their similar efficacy in reducing pruritus and lesion size, while also considering differences in safety profiles and treatment considerations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
5. Two systemic treatments are now FDA-approved for prurigo nodularis: dupilumab and nevolizumabnemolizumab. Can you briefly discuss these two 2 agents, including similarities/differences as well as efficacy and safety?
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5